SynbioVen was created in 2022 as the UK's dedicated investment vehicle for synthetic biology — a focused bet that synbio would become a major technology platform and that the UK, with its strong academic base, needed a purpose-built funding mechanism. The fund is relatively modest at £20M total, with £15M earmarked for proof-of-concept through seed-stage synbio startups. But the real story is the ...
United States
Berlin, Germany
New York, United States
San Francisco, United States
Buenos Aires, Argentina
Auckland, New Zealand